Showing results (151-160 of 201) with videos related to

Sort By:
Pageof 21
Bone|January 22, 2013
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myelomaSamantha Pozzi, Mariateresa Fulciniti, Hua Yan, et al.
Breast (Edinburgh, Scotland)|April 16, 2018
Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancerAnju Gangadharan, Themba Nyirenda, Kishan Patel, et al.
Aging and Disease|June 6, 2017
Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related TauopathiesDiana L Castillo-Carranza, Ashley N Nilson, Candice E Van Skike, et al.
Blood Neoplasia|June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomasPaola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Advances in Cancer Research|July 28, 2019
Clinical and translational advances in esophageal squamous cell carcinomaZachary Wilmer Reichenbach, Mary Grace Murray, Reshu Saxena, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 7, 2020
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell LymphomaPierluigi Porcu, Stacie Hudgens, Steven Horwitz, et al.
Molecular Cancer Therapeutics|April 8, 2010
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myelomaDiana Cirstea, Teru Hideshima, Scott Rodig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.
Cancer Immunology Research|June 14, 2018
Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint ProfileChristiane Querfeld, Samantha Leung, Patricia L Myskowski, et al.
The Journal of Experimental Medicine|February 14, 2018
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancerKevin Shee, Wei Yang, John W Hinds, et al.
Pageof 21